134 related articles for article (PubMed ID: 34774650)
41. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
Hauck CR; Ye H; Chen PY; Gustafson GS; Limbacher A; Krauss DJ
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):108-114. PubMed ID: 28586946
[TBL] [Abstract][Full Text] [Related]
42. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
43. [Effect of PSA nadir and the time to nadir in the disease-free period in localized prostatic carcinoma treated with radical radiation].
Cambeiro M; Azinovic I; Villafranca E; Moreno-Jiménez M; Cañón R; Aristu JJ; Beltrán C; López-Picazo JM; Fernández J; Rebollo J
Rev Med Univ Navarra; 2001; 45(1):20-8. PubMed ID: 11488204
[TBL] [Abstract][Full Text] [Related]
44. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
Pickles T;
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1355-9. PubMed ID: 16406391
[TBL] [Abstract][Full Text] [Related]
45. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
[TBL] [Abstract][Full Text] [Related]
46. Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy.
Ennis RD; Malyszko BK; Heitjan DF; Rubin MA; O'Toole KM; Schiff PB
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):511-7. PubMed ID: 9635696
[TBL] [Abstract][Full Text] [Related]
47. Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer.
Miszczyk M; Magrowski Ł; Masri O; Jabłon'ska I; Nowicka Z; Krzysztofiak T; Wojcieszek P; Lipka-Rajwa A; Ciepał J; Depowska G; Chimiak K; Bylica G; Płoszka K; Łaszczych M; Majewski W
J Contemp Brachytherapy; 2022 Feb; 14(1):15-22. PubMed ID: 35233230
[TBL] [Abstract][Full Text] [Related]
48. Multiparametric MRI as a Predictor of PSA Response in Patients Undergoing Stereotactic Body Radiation Therapy for Prostate Cancer.
Rayn K; Deutsch I; Jeffers B; Lee A; Lavrova E; Gallitto M; Mayeda M; Hwang M; Yu J; Spina C; Koutcher L
Adv Radiat Oncol; 2024 Mar; 9(3):101408. PubMed ID: 38304110
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Stock RG; Klein TJ; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
[TBL] [Abstract][Full Text] [Related]
50. Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy.
Boehle A; Katic K; König IR; Robrahn-Nitschke I; Brandenburg B
Brachytherapy; 2020; 19(1):24-32. PubMed ID: 31629640
[TBL] [Abstract][Full Text] [Related]
51. A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.
Hegde JV; Collins SP; Fuller DB; King CR; Demanes DJ; Wang PC; Kupelian PA; Steinberg ML; Kamrava M
Am J Clin Oncol; 2018 May; 41(5):502-507. PubMed ID: 27322703
[TBL] [Abstract][Full Text] [Related]
52. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.
Ahmed KA; Davis BJ; Mynderse LA; Slezak JM; Bergstralh EJ; Wilson TM; Choo CR
Radiat Oncol; 2014 Jul; 9():171. PubMed ID: 25074478
[TBL] [Abstract][Full Text] [Related]
53. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
54. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
55. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.
Singh AK; Guion P; Susil RC; Citrin DE; Ning H; Miller RW; Ullman K; Smith S; Crouse NS; Godette DJ; Stall BR; Coleman CN; Camphausen K; Ménard C
Radiat Oncol; 2006 Aug; 1():28. PubMed ID: 16914054
[TBL] [Abstract][Full Text] [Related]
56. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
57. The biochemical efficacy of primary cryoablation combined with prolonged total androgen suppression compared with radiotherapy on high-risk prostate cancer: a 3-year pilot study.
Ko YH; Kang SH; Park YJ; Park HS; Moon du G; Lee JG; Yoon DK; Kim JJ; Cheon J
Asian J Androl; 2010 Nov; 12(6):827-34. PubMed ID: 20711215
[TBL] [Abstract][Full Text] [Related]
58. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.
Anwar M; Weinberg V; Seymour Z; Hsu IJ; Roach M; Gottschalk AR
Radiat Oncol; 2016 Jan; 11():8. PubMed ID: 26792201
[TBL] [Abstract][Full Text] [Related]
59. Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
Mbeutcha A; Chauveinc L; Bondiau PY; Chand ME; Durand M; Chevallier D; Amiel J; Kee DL; Hannoun-Lévi JM
Radiat Oncol; 2017 Mar; 12(1):49. PubMed ID: 28274241
[TBL] [Abstract][Full Text] [Related]
60. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
